REFLUDAN [lepirudin (rDNA) for injection]: the first direct thrombin inhibitor FDA-approved for heparin induced thrombocytopenia (HIT)

Learn more about the benefits of REFLUDAN
This section contains REFLUDAN laboratory and clinical efficacy data
This section contains efficacy data from principal clinical trials and a drug monitoring program of REFLUDAN for the treatment of heparin induced thrombocytopenia (HIT)
This section contains data from a prospective, historically-controlled trial to evaluate the anticoagulant efficacy of REFLUDAN in patients with confirmed heparin induced thrombocytopenia (HIT)
This section describes the combined risk of death, limb amputation, or new thromboembolic complication (TEC) in patients treated with REFLUDAN for heparin induced thrombocytopenia (HIT)
This section contains information regarding the safe administration of REFLUDAN for the treatment of heparin induced thrombocytopenia (HIT)
This section describes the dosage and administration of REFLUDAN in the treatment of heparin induced thrombocytopenia (HIT)
Heparin induced thrombocytopenia
A summary of pivotal trial data for REFLUDAN is covered in this section
This section provides access to a variety of resources to obtain in-depth information on heparin induced thrombocytopenia (HIT) and REFLUDAN
Find out what your peers are saying about heparin induced thrombocytopenia (HIT)...

©2007 Bayer Healthcare Pharmaceuticals Inc. All rights reserved.
H.I.T. BACK with REFLUDAN to protect life and limb
Laboratory Efficacy
Respond with REFLUDAN to prevent
further complications of HIT
REFLUDAN ensures uninterrupted therapeutic anticoagulation and promotes rapid recovery of platelets1

   91% of patients achieved platelet recovery*†
91% of patients taking REFLUDAN for the treatment of heparin induced thrombocytopenia (HIT) achieved platelet recovery
   At least 75% of patients demonstrated a rapid increase in platelet count, with complete platelet recovery by Day 3†‡4

For information on clinical outcomes, see Clinical Efficacy, or view the REFLUDAN Product Monograph.



* Results from 55 evaluable patients with HIT and baseline TECs assigned to REFLUDAN therapy in a prospective, historically controlled trial (HAT-1) to evaluate REFLUDAN anticoagulant efficacy in patients with confirmed HIT.
† Platelet recovery was defined as an increase in platelet count of at least 30% of nadir to values >100,000/µL.
‡ Results from 62 evaluable patients with acute HIT treated with REFLUDAN in a prospective, historically controlled trial (HAT-1).



Clinical Efficacy
Laboratory Efficacy
Clinical Efficacy Data

Terms of Use      Privacy Policy      About Our New Company
Bayer Healthcare Pharmaceuticals